The state of California currently has 18 active clinical trials seeking participants for Amyotrophic Lateral Sclerosis research studies. These trials are conducted in various cities, including Los Angeles, San Francisco, San Diego and Sacramento.
Feasibility of the BrainGate2 Neural Interface System in Persons With Tetraplegia
NCT05724173
Recruiting
The purpose of this study is to obtain preliminary device safety information and demonstrate proof of principle (feasibility) of the ability of people with tetraplegia to control a computer cursor and other assistive devices with their thoughts.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
10/30/2023
Locations: Stanford University School of Medicine, Stanford, California
Conditions: Anarthria, Dysarthria, Tetraplegia, Spinal Cord Injuries, Amyotrophic Lateral Sclerosis, Brain Stem Infarctions, Locked in Syndrome, Muscular Dystrophies
Register for Updates
A Study to Evaluate, Safety, Tolerability, Pharmacodynamic (PD) Markers and Pharmacokinetics (PK) of AP-101 in Participants With Amyotrophic Lateral Sclerosis (ALS)
NCT05039099
Recruiting
The purpose of this study is to evaluate the safety, tolerability, PK, and PD of AP-101 in participants with fALS and sALS.
Gender:
All
Ages:
18 years and above
Trial Updated:
08/02/2023
Locations: UC San Diego, ACTRI, La Jolla, California
Conditions: Amyotrophic Lateral Sclerosis
Register for Updates
Intermuscular Coherence as a Biomarker for ALS
NCT05104710
Recruiting
The specific aims of this study are to: Determine if a painless and quick measurement of muscle activity using surface electrodes can help with the diagnosis of ALS. Specifically, we ask if a measure of intermuscular coherence (IMC-βγ), when added to current diagnostic criteria (Awaji criteria), can differentiate ALS from mimic diseases more accurately and earlier than currently possible. Characterize IMC-βγ in neurotypical subjects by age, sex, race, and ethnicity. Follow a cohort of ALS patie... Read More
Gender:
All
Ages:
Between 20 years and 80 years
Trial Updated:
05/16/2023
Locations: University of California Center for Clinical Research, Irvine, California
Conditions: Amyotrophic Lateral Sclerosis
Register for Updates
Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients
NCT03127267
Recruiting
The objective is to compare the efficacy and safety of masitinib in combination with riluzole versus matched placebo in combination with riluzole for the treatment of Amyotrophic Lateral Sclerosis (ALS).
Gender:
All
Ages:
Between 18 years and 81 years
Trial Updated:
04/14/2023
Locations: University of Southern California, Los Angeles, California
Conditions: Amyotrophic Lateral Sclerosis
Register for Updates
Study of ANX005 in Adults With Amyotrophic Lateral Sclerosis (ALS)
NCT04569435
Recruiting
This study is a multi-center, open-label study of intravenous (IV) ANX005 in participants with ALS.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/23/2023
Locations: Annexon Investigational Site 01, Orange, California +1 locations
Conditions: Amyotrophic Lateral Sclerosis
Register for Updates
AMDX-2011P Retinal Tracer in Subjects With Neurodegenerative Diseases Associated With Amyloidogenic Proteinopathy
NCT05542576
Recruiting
The purpose of this research study is to assess safety and tolerability of a single intravenous (given through a vein) dose of the investigational retinal tracer AMDX-2011P in patients with neurodegenerative diseases (Parkinson's disease and ALS).
Gender:
All
Ages:
18 years and above
Trial Updated:
01/31/2023
Locations: Eye Research Foundation, Newport Beach, California +1 locations
Conditions: Parkinson Disease, Amyotrophic Lateral Sclerosis
Register for Updates